398 related articles for article (PubMed ID: 9111297)
1. Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
Messer WS; Abuh YF; Liu Y; Periyasamy S; Ngur DO; Edgar MA; El-Assadi AA; Sbeih S; Dunbar PG; Roknich S; Rho T; Fang Z; Ojo B; Zhang H; Huzl JJ; Nagy PI
J Med Chem; 1997 Apr; 40(8):1230-46. PubMed ID: 9111297
[TBL] [Abstract][Full Text] [Related]
2. 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
Pei XF; Gupta TH; Badio B; Padgett WL; Daly JW
J Med Chem; 1998 Jun; 41(12):2047-55. PubMed ID: 9622546
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of human m1 muscarinic acetylcholine receptors with double mutations at the junction of TM VI and the third extracellular domain.
Huang XP; Williams FE; Peseckis SM; Messer WS
J Pharmacol Exp Ther; 1998 Sep; 286(3):1129-39. PubMed ID: 9732369
[TBL] [Abstract][Full Text] [Related]
4. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.
Wood MD; Murkitt KL; Ho M; Watson JM; Brown F; Hunter AJ; Middlemiss DN
Br J Pharmacol; 1999 Apr; 126(7):1620-4. PubMed ID: 10323594
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of 5-(4-alkylsulfanyl-[1, 2, 5]thiadiazol-3-yl)-3-methyl-1, 2, 3, 4-tetrahydropyrimidine oxalate salts and their evaluation as muscarinic receptor agonists.
Jung MH; Park JG; Park WK
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):230-5. PubMed ID: 12916057
[TBL] [Abstract][Full Text] [Related]
6. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
[TBL] [Abstract][Full Text] [Related]
7. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
Christopoulos A; Pierce TL; Sorman JL; El-Fakahany EE
Mol Pharmacol; 1998 Jun; 53(6):1120-30. PubMed ID: 9614217
[TBL] [Abstract][Full Text] [Related]
8. Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors.
Huang XP; Nagy PI; Williams FE; Peseckis SM; Messer WS
Br J Pharmacol; 1999 Feb; 126(3):735-45. PubMed ID: 10188986
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders.
Cao Y; Zhang M; Wu C; Lee S; Wroblewski ME; Whipple T; Nagy PI; Takács-Novák K; Balázs A; Torös S; Messer WS
J Med Chem; 2003 Sep; 46(20):4273-86. PubMed ID: 13678406
[TBL] [Abstract][Full Text] [Related]
10. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
[TBL] [Abstract][Full Text] [Related]
11. Enantiomeric N-methyl-4-piperidyl benzilates as muscarinic receptor ligands: Radioligand binding studies and docking studies to models of the three muscarinic receptors M1, M2 and M3.
Selent J; Brandt W; Pamperin D; Göber B
Bioorg Med Chem; 2006 Mar; 14(6):1729-36. PubMed ID: 16290166
[TBL] [Abstract][Full Text] [Related]
12. 1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M1 agonists: structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives.
Jeppesen L; Olesen PH; Hansen L; Sheardown MJ; Thomsen C; Rasmussen T; Jensen AF; Christensen MS; Rimvall K; Ward JS; Whitesitt C; Calligaro DO; Bymaster FP; Delapp NW; Felder CC; Shannon HE; Sauerberg P
J Med Chem; 1999 Jun; 42(11):1999-2006. PubMed ID: 10354408
[TBL] [Abstract][Full Text] [Related]
13. Aliphatic and heterocyclic analogues of arecaidine propargyl ester. Structure-activity relationships of mono- and bivalent ligands at muscarinic M1 (M4), M2 and M3 receptor subtypes.
Moser U; Gubitz C; Galvan M; Immel-Sehr A; Lambrecht G; Mutshcler E
Arzneimittelforschung; 1995 Apr; 45(4):449-55. PubMed ID: 7779140
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biochemical activity of novel amidine derivatives as m1 muscarinic receptor agonists.
Ojo B; Dunbar PG; Durant GJ; Nagy PI; Huzl JJ; Periyasamy S; Ngur DO; el-Assadi AA; Hoss WP; Messer WS
Bioorg Med Chem; 1996 Oct; 4(10):1605-15. PubMed ID: 8931930
[TBL] [Abstract][Full Text] [Related]
15. Effects of agonist efficacy on desensitization of phosphoinositide hydrolysis mediated by m1 and m3 muscarinic receptors expressed in Chinese hamster ovary cells.
Hu J; Wang SZ; el-Fakahany EE
J Pharmacol Exp Ther; 1991 Jun; 257(3):938-45. PubMed ID: 1710663
[TBL] [Abstract][Full Text] [Related]
16. Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
Malviya M; Kumar YC; Mythri RB; Venkateshappa C; Subhash MN; Rangappa KS
Bioorg Med Chem; 2009 Aug; 17(15):5526-34. PubMed ID: 19595599
[TBL] [Abstract][Full Text] [Related]
17. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
Bromidge SM; Brown F; Cassidy F; Clark MS; Dabbs S; Hadley MS; Hawkins J; Loudon JM; Naylor CB; Orlek BS; Riley GJ
J Med Chem; 1997 Dec; 40(26):4265-80. PubMed ID: 9435896
[TBL] [Abstract][Full Text] [Related]
18. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
Vamvakidès A
Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
Dunbar PG; Durant GJ; Rho T; Ojo B; Huzl JJ; Smith DA; el-Assadi AA; Sbeih S; Ngur DO; Periyasamy S
J Med Chem; 1994 Aug; 37(17):2774-82. PubMed ID: 8064804
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the binding and activity at muscarinic receptor subtypes and chimeras.
Tejada FR; Nagy PI; Xu M; Wu C; Katz T; Dorsey J; Rieman M; Lawlor E; Warrier M; Messer WS
J Med Chem; 2006 Dec; 49(25):7518-31. PubMed ID: 17149881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
